← Back to guidelines
Ophthalmology37 papers

Optic neuritis

Last edited: 4/14/2026

Overview

Optic neuritis is an inflammatory condition affecting the optic nerve, often associated with multiple sclerosis (MS) and characterized by acute visual impairment, pain with eye movement, and visual field defects 13.

Diagnosis

  • Clinical Presentation: Acute visual loss, pain with eye movement, and visual field defects 3.
  • Recommended Tests:
  • - Ophthalmologic Examination: Detailed visual acuity testing, fundoscopy, and color vision assessment 3. - Visual Evoked Potentials (VEP): To assess optic nerve dysfunction 12. - Contrast Modulated Steady State Visual Evoked Potentials (CMSS-VEPs): Sensitive non-invasive functional investigation 13.
  • Grading: Often assessed using the Kurtzke Expanded Disability Status Scale (EDSS) for neurological impact 10.
  • Management

  • First-Line Treatment:
  • - High-Dose Corticosteroids: Typically intravenous methylprednisolone to reduce inflammation 356.
  • Adjunctive Treatments:
  • - Disease-Modifying Agents (DMAs): Used in recurrent cases or high risk of MS, such as interferon beta or glatiramer acetate 56. - Vitamin D Supplementation: Evidence mixed; potential role in prevention or management under investigation 1.

    Special Populations

  • Pregnancy: Management strategies need careful consideration due to potential risks of DMAs; corticosteroids remain a mainstay 5.
  • Elderly: Similar treatment approaches as younger adults, but with closer monitoring for comorbidities and medication interactions 5.
  • Comorbidities: Management should account for concurrent conditions; individualized treatment plans are advised 5.
  • Key Recommendations

  • Initiate high-dose corticosteroids for acute optic neuritis to improve visual outcomes (Evidence: Strong 356).
  • Consider disease-modifying agents in patients with recurrent optic neuritis or high risk of developing multiple sclerosis (Evidence: Moderate 56).
  • Monitor visual function and quality of life post-treatment using tools like the NEI-VFQ to assess long-term outcomes (Evidence: Moderate 10).
  • Evaluate vitamin D status and supplementation in patients with optic neuritis, given potential associations with disease risk (Evidence: Weak 1).
  • Avoid routine association with vaccines causing optic neuritis based on current VAERS data; no significant association detected 24.
  • References

    1 Gaffney PJ, Gupta RK. Vitamin supplementation in the treatment of optic neuritis: A systematic review and meta-analysis. Multiple sclerosis and related disorders 2025. link 2 Jaffry M, Aftab OM, Mostafa FB, Faiz I, Jaffry K, Mandava K et al.. Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2023. link 3 Beisse F, Beisse C. Current Recommendations on Optic Neuritis. Klinische Monatsblatter fur Augenheilkunde 2020. link 4 Baxter R, Lewis E, Fireman B, DeStefano F, Gee J, Klein NP. Case-centered Analysis of Optic Neuritis After Vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016. link 5 Biousse V, Calvetti O, Drews-Botsch CD, Atkins EJ, Sathornsumetee B, Newman NJ. Management of optic neuritis and impact of clinical trials: an international survey. Journal of the neurological sciences 2009. link 6 Lueck CJ, Danesh-Meyer HV, Margrie FJ, Drews-Botsch C, Calvetti O, Newman NJ et al.. Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2008. link 7 Frohman L. The approach to bilateral simultaneous isolated optic neuritis. The British journal of ophthalmology 2006. link 8 Agostoni E, Frigerio R, Protti A. Controversies in optic neuritis pain diagnosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2005. link 9 Ghosh A, Kelly SP, Mathews J, Cooper PN, Macdermott N. Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England. Journal of neurology, neurosurgery, and psychiatry 2002. link 10 Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Investigative ophthalmology & visual science 2000. link 11 Trobe JD, Sieving PC, Guire KE, Fendrick AM. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology 1999. link90482-7) 12 Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO. Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Controlled clinical trials 1993. link90016-7) 13 Spileers W, Orban GA, Maes H, Missotten L. CMSS-VEPs: contrast modulated steady state visual evoked potentials: its neuronal origin and clinical use. Documenta ophthalmologica. Advances in ophthalmology 1988. link 14 Ringens PJ, van Lith GH, vd Poel H. The pattern-elicited electroretinogram. II. Retinal responses in retrobulbar neuritis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 1986. link

    Original source

    1. [1]
      Vitamin supplementation in the treatment of optic neuritis: A systematic review and meta-analysis.Gaffney PJ, Gupta RK Multiple sclerosis and related disorders (2025)
    2. [2]
      Optic Neuritis After COVID-19 Vaccination: An Analysis of the Vaccine Adverse Event Reporting System.Jaffry M, Aftab OM, Mostafa FB, Faiz I, Jaffry K, Mandava K et al. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society (2023)
    3. [3]
      Current Recommendations on Optic Neuritis.Beisse F, Beisse C Klinische Monatsblatter fur Augenheilkunde (2020)
    4. [4]
      Case-centered Analysis of Optic Neuritis After Vaccines.Baxter R, Lewis E, Fireman B, DeStefano F, Gee J, Klein NP Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2016)
    5. [5]
      Management of optic neuritis and impact of clinical trials: an international survey.Biousse V, Calvetti O, Drews-Botsch CD, Atkins EJ, Sathornsumetee B, Newman NJ Journal of the neurological sciences (2009)
    6. [6]
      Management of acute optic neuritis: a survey of neurologists and ophthalmologists in Australia and New Zealand.Lueck CJ, Danesh-Meyer HV, Margrie FJ, Drews-Botsch C, Calvetti O, Newman NJ et al. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2008)
    7. [7]
      The approach to bilateral simultaneous isolated optic neuritis.Frohman L The British journal of ophthalmology (2006)
    8. [8]
      Controversies in optic neuritis pain diagnosis.Agostoni E, Frigerio R, Protti A Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2005)
    9. [9]
      Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England.Ghosh A, Kelly SP, Mathews J, Cooper PN, Macdermott N Journal of neurology, neurosurgery, and psychiatry (2002)
    10. [10]
      The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial.Cole SR, Beck RW, Moke PS, Gal RL, Long DT Investigative ophthalmology & visual science (2000)
    11. [11]
      The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists.Trobe JD, Sieving PC, Guire KE, Fendrick AM Ophthalmology (1999)
    12. [12]
      Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT).Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO Controlled clinical trials (1993)
    13. [13]
      CMSS-VEPs: contrast modulated steady state visual evoked potentials: its neuronal origin and clinical use.Spileers W, Orban GA, Maes H, Missotten L Documenta ophthalmologica. Advances in ophthalmology (1988)
    14. [14]
      The pattern-elicited electroretinogram. II. Retinal responses in retrobulbar neuritis.Ringens PJ, van Lith GH, vd Poel H Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (1986)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG